Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Efficacy of a Wearable Noninvasive Neuromodulation Device

NCT: NCT07171489 · RECRUITING

NCT IDNCT07171489
StatusRECRUITING
Start Date2026-07
Completion2029-11
SponsorUniversity of Michigan (OTHER)
First posted
Last updated

Brief Summary

The aim of this study is to investigate the potential of transcutaneous neuromodulation (TNM) to treat slow colonic transit and constipation, termed the Neurogenic bowel dysfunction (NBD), in people with SCI. In this project, the study team will investigate the impact of an active treatment intervention vs. a sham control intervention on NBD symptoms in patients with SCI. The study hypotheses: * The proposed TNM treatment at a leg point will reduce NBD symptoms between baseline and post-therapy, when compared to the sham-TNM treatment. * The therapeutic effect of TNM to improve the NBD symptoms is associated with improvement of the autonomic function in SCI patients.

Frequently Asked Questions

What is Efficacy of a Wearable Noninvasive Neuromodulation Device?

Efficacy of a Wearable Noninvasive Neuromodulation Device is a clinical trial registered under NCT07171489. Current status: RECRUITING.

What is the status of NCT07171489?

The current status of NCT07171489 (Efficacy of a Wearable Noninvasive Neuromodulation Device) is: RECRUITING.

When did Efficacy of a Wearable Noninvasive Neuromodulation Device start?

Efficacy of a Wearable Noninvasive Neuromodulation Device started on 2026-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.